http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008012110-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3bccd06fe05613a410cce708e9e4c287
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8f388bb28dd75e46182026ea4360ea9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5d7342b2c609e16ee92682b3c7e1aa8b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a89514464d02d75ef2065a449fb0e617
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_38dcd2e2ef1d854686caa844bb3b6ae5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d7f0d37dc32173d6b3f407d30ae4f59e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d2de06c921ad7552c6826f5d22a28800
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-407
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-407
filingDate 2007-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77365922fbef6f8ec0202851281070a8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c84bd8f3b1e99cd0af15d000e01c4178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_589397a12e3fe6e72308cd1647252184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e677bde43d53e6568722a332b5d9d2b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ec6b44b0c436887169d05e12b729740
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f25747f9d9ff79060f3b1d9a2c4cf56d
publicationDate 2008-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2008012110-A3
titleOfInvention Annellated pyrrole compounds for cancer management
abstract The present invention relates to the use of annellated pyrrole compounds and in particular ML3000 (licofelone), salts or derivatives thereof, for cancer management, and in general to the use of a compound of Formula (I): wherein the variables have the meanings given in the present description, for the prevention and/or treatment of neoplasia, in particular neoplasia selected from the group consisting of papilloma, carcinoma, adenoma and adenocarcinoma, e. g. human airway or colorectal carcinoma, preferably fast-growing, multidrug resistant and/or COX-2 negative neoplasia. The invention further relates to pharmaceutical compositions for the aforesaid purposes, comprising annellated pyrrole compounds and in particular ML3000 (licofelone), optical isomers, salts or derivatives thereof, as well as to a method of treating and/or preventing neoplasia and/or restoring the ability to undergo apoptosis in a cell having lost the same. This treatment ameliorates, diminishes, actively treats, reverses or prevents any disease related to insufficient apoptosis, in particular neoplasia, and it may be combined with irradiation, heating and treatment with a cytotoxic agent for preventive and/or curative purposes.
priorityDate 2006-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-10004157-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03020267-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005129764-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-1940551-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID133021
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419514355

Total number of triples: 30.